Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin
Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved..
Haploidentical donor (haplo-) hematopoietic stem cell transplantation (HSCT) with post-transplantation cyclophosphamide (PTCy) is now performed on a large scale worldwide. Our patient outcomes did not completely reflect the results published by other groups. We herein present the results of 60 patients with hematologic malignancies treated homogeneously on a modified version of the standard protocol by adding ATG as an additional graft-versus-host disease (GVHD) prophylaxis measure. This was a retrospective analysis of 60 haplo-HSCT recipients using a myeloablative conditioning regimen with antithymocyte globulin and PTCy for GVHD prophylaxis. At 5 years, overall survival was 59.2%, relapse-free survival (RFS) was 48.6%, and chronic GVHD (cGVHD) and relapse-free survival was 40%. The median time to neutrophil and platelet engraftment was 16 days and 28.5 days, respectively. The rates of grade II-IV acute GVHD and extensive cGVHD were 46.7% and 23.3%, respectively. The cumulative incidence of relapse was 30%, nonrelapse mortality was 21.6%, and transplantation-related mortality was 11%. Higher Disease Risk Index and 50% HLA match were associated with lower RFS. Female donor to male recipient and older donor age were associated with an elevated risk of cGVHD. The use of PTCy might not yield the same results in different populations. Many remaining questions need to be addressed in randomized trials, including optimal graft source and donor, date of calcineurin inhibitor initiation, personalized or targeted dose of PTCy, immune reconstitution, and others.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Transplantation and cellular therapy - 30(2024), 3 vom: 06. März, Seite 312.e1-312.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Fakih, Riad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8N3DW7272P |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtct.2024.01.054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366759981 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366759981 | ||
| 003 | DE-627 | ||
| 005 | 20240326235215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtct.2024.01.054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM366759981 | ||
| 035 | |a (NLM)38185379 | ||
| 035 | |a (PII)S2666-6367(24)00055-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Fakih, Riad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Haploidentical donor (haplo-) hematopoietic stem cell transplantation (HSCT) with post-transplantation cyclophosphamide (PTCy) is now performed on a large scale worldwide. Our patient outcomes did not completely reflect the results published by other groups. We herein present the results of 60 patients with hematologic malignancies treated homogeneously on a modified version of the standard protocol by adding ATG as an additional graft-versus-host disease (GVHD) prophylaxis measure. This was a retrospective analysis of 60 haplo-HSCT recipients using a myeloablative conditioning regimen with antithymocyte globulin and PTCy for GVHD prophylaxis. At 5 years, overall survival was 59.2%, relapse-free survival (RFS) was 48.6%, and chronic GVHD (cGVHD) and relapse-free survival was 40%. The median time to neutrophil and platelet engraftment was 16 days and 28.5 days, respectively. The rates of grade II-IV acute GVHD and extensive cGVHD were 46.7% and 23.3%, respectively. The cumulative incidence of relapse was 30%, nonrelapse mortality was 21.6%, and transplantation-related mortality was 11%. Higher Disease Risk Index and 50% HLA match were associated with lower RFS. Female donor to male recipient and older donor age were associated with an elevated risk of cGVHD. The use of PTCy might not yield the same results in different populations. Many remaining questions need to be addressed in randomized trials, including optimal graft source and donor, date of calcineurin inhibitor initiation, personalized or targeted dose of PTCy, immune reconstitution, and others | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ATG | |
| 650 | 4 | |a Haploidentical | |
| 650 | 4 | |a Myeloablative | |
| 650 | 4 | |a PTCy | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Nassani, Momen |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Walid |e verfasserin |4 aut | |
| 700 | 1 | |a Hanbali, Amr |e verfasserin |4 aut | |
| 700 | 1 | |a Almohareb, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhri, Naeem |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharif, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Alfraih, Feras |e verfasserin |4 aut | |
| 700 | 1 | |a Shaheen, Marwan |e verfasserin |4 aut | |
| 700 | 1 | |a Alhayli, Saud |e verfasserin |4 aut | |
| 700 | 1 | |a Alkhaldi, Hanan |e verfasserin |4 aut | |
| 700 | 1 | |a Alshaibani, Alfadel |e verfasserin |4 aut | |
| 700 | 1 | |a Alotaibi, Ahmad S |e verfasserin |4 aut | |
| 700 | 1 | |a Alahmari, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Alamer, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Tarig, Abrar |e verfasserin |4 aut | |
| 700 | 1 | |a Youniss, Riad |e verfasserin |4 aut | |
| 700 | 1 | |a Albabtain, Abdulwahab A |e verfasserin |4 aut | |
| 700 | 1 | |a Alfayez, Mansour |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Ayman |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Syed Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Hazzaa |e verfasserin |4 aut | |
| 700 | 1 | |a Aljurf, Mahmoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation and cellular therapy |d 2021 |g 30(2024), 3 vom: 06. März, Seite 312.e1-312.e7 |w (DE-627)NLM307596486 |x 2666-6367 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:06 |g month:03 |g pages:312.e1-312.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtct.2024.01.054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 06 |c 03 |h 312.e1-312.e7 | ||